IL-STATS-PERFORM
7.10.2019 13:02:09 CEST | Business Wire | Press release
Today, Stats Perform , the revolutionary leader in sports AI and data, and Control Risks , the leading specialist risk consultancy, announce a unique partnership to bring best-in-class comprehensive sports integrity solutions to the market.
Through Stats Perform’s Integrity Unit, sports industry stakeholders such as rights holders, International Federations and Governing Bodies will be able to access Control Risks’ global investigative capabilities to help drive out corruption and match-fixing. Integrity units and compliance departments will have access to a full range of solutions, including forensic accounting, data analytics and traditional investigative capabilities, to manage risk or conduct investigations.
The partnership will combine Stats Perform’s offering across prevention, detection and investigation with Control Risks’ global investigative practice and experience in building resilient and compliant governance programmes. Together, they will help stakeholders ensure their integrity, anti-doping and compliance programmes are fit-for-purpose, while protecting the long-term value of their brands.
Furthermore, global sport stakeholders will be able to utilise the full suite of services the partnership has to offer, whether it is a team requiring due diligence on a potential investor, sponsor or new signing, or a business looking to partner with a new league or competition. The partnership will enable sports stakeholders to manage both sporting integrity and business risks in one place.
Nick Allan , CEO of Control Risks, said: “We are delighted to announce this exciting new partnership with Stats Perform to help the sports industry in its desire to combat the threats to its integrity posed by corruption and match-fixing. Our global investigations capabilities will enable all stakeholders, to be able to call on our support as part of their contract with Stats Perform.”
Mike Perez , COO of Stats Perform, said: “As the sports industry goes through a data revolution, our existing integrity services will benefit from complementary investigative capabilities to identify, investigate and respond to threats. We are very pleased to move forward with Control Risks who have the global capabilities to match our aspirations.”
Jonny Gray , Global Head of Sport at Control Risks, said: “This is a very exciting development as the sports industry looks for comprehensive support to combat existential threats to its integrity, trust and value. It gives Stats Perform’s clients the opportunity for a complete integrity solution.”
Jake Marsh , Head of Integrity at Stats Perform, said: “Sports stakeholders face a variety of governance and integrity challenges. Our role is not simply to help them identify and mitigate risk, but to assist in investigation and response. Our partnership with Control Risks helps us do that and provide a better, more complete service to our clients.”
About Control Risks
Control Risks is a specialist risk consulting firm that helps create secure, compliant and resilient organizations. We believe that taking risks is essential to success, so we provide the insight and intelligence you need to realize opportunities and grow.
Our experts across 34 offices bring experience in prosecution and law enforcement, accounting, management consulting, regional business intelligence, forensic technology and cyber security to advise the world’s largest multinational companies on major regulatory issues, conduct complex cross-border investigations and build robust compliance programs.
Learn more at www.controlrisk.com/sport
About Stats Perform
Stats Perform collects the richest sports data in the world and transforms it through revolutionary artificial intelligence (AI) to unlock the most in-depth insights for media and technology, betting and team performance. With company roots dating back almost 40 years, Stats Perform embraces and solves the dynamic nature of sport – be that for digital and broadcast media with differentiated storytelling, tech companies with reliable and fast data to power their innovations, sportsbooks with in-play betting and integrity services, or teams with first-of-its-kind AI analysis software. As the leading sports data and AI company, Stats Perform works with the top global sports media, tech companies, sportsbooks, teams and leagues.
For more information, visit StatsPerform.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005277/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom